Literature DB >> 18222551

Contemporary treatment and adherence to guidelines in women and men with acute coronary syndromes.

Mady Moriel1, Dan Tzivoni, Solomon Behar, Doron Zahger, Hanoch Hod, David Hasdai, Amir Sandach, Shmuel Gottlieb.   

Abstract

BACKGROUND: Historically gender differences existed in treatment and outcome of patients with acute myocardial infarction (MI). AIM: To assess gender aspects of contemporary treatment and adherence to ACC/AHA Class-I Treatment Guidelines in patients with acute coronary syndrome (ACS).
METHODS: We studied 2024 consecutive patients (519 women, 26%); 1026 (51%) with ST-elevation (STE)-MI and 998 (49%) patients with non-STE (NSTE), during a nationwide ACS-survey, conducted during 2-months in 2004.
RESULTS: Women were older than men (71 vs. 59 in STEMI; 71 vs. 64 years in NSTE-ACS patients), and had worse cardiovascular risk profiles. In STEMI-patients, acute reperfusion was less frequent in women than in men (53% vs. 63%, respectively, p=0.01; non-significant after age-adjustment). At discharge, fewer women received ACE-inhibitors/ARBs (71% vs. 75%, respectively; OR(age-adj)=0.69[0.48-0.98]). Among NSTE-ACS patients, fewer women received IIb/IIIa-inhibitors (12% vs. 21%, respectively, p=0.007; OR(age-adj)=0.58[0.36-0.96]) and clopidogrel at discharge (49% vs. 59%, respectively, p=0.005; OR(age-adj) 0.75[0.56-1.01]). No gender differences were noted in utilization of aspirin, beta-blockers or statins. Age-adjusted and covariate-adjusted mortality rates were comparable in women and men with STEMI (at 7-days 4.3% vs. 4.1%; OR(adj)=0.95[0.47-1.87] and at 1-year 13.8% vs. 9.8%, hazard ratio [HR(adj)]=1.11[0.73-1.70], respectively); in women and men with NSTE-ACS (at 7-days 1.3% vs. 2.1%, OR(adj)=0.65[0.20-1.76], and at 1-year 12.0% vs. 11.3%; HR(adj)=1.19[0.80-1.77], respectively).
CONCLUSIONS: In 2004, adherence to ACC/AHA Class-I Treatment Guidelines in ACS-patients was satisfactory. Relative underutilization of acute reperfusion was noted among STEMI patients, without gender differences after age-adjustment. At discharge, less women received ACE-inhibitors/ARBs. Among NSTE-ACS patients, less women than men received IIb/IIIa-inhibitors, and clopidogrel at discharge. Contemporary ACS management was associated with similar adjusted outcome in women and men.

Entities:  

Mesh:

Year:  2008        PMID: 18222551     DOI: 10.1016/j.ijcard.2007.09.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Sex differences in the treatment and outcome of patients with acute coronary syndrome after percutaneous coronary intervention: a population-based study.

Authors:  Chen-Fang Lin; Li-Jiuan Shen; Fei-Yuan Hsiao; Churn-Shiouh Gau; Fe-Lin Lin Wu
Journal:  J Womens Health (Larchmt)       Date:  2013-11-28       Impact factor: 2.681

2.  Clinical profile and 30-day outcome of women with acute coronary syndrome as a first manifestation of ischemic heart disease: A single-center observational study.

Authors:  Veena Nanjappa; Gopi Aniyathodiyil; R Keshava
Journal:  Indian Heart J       Date:  2016-01-18

3.  Exploring patients' reasons for discontinuance of heart medications.

Authors:  Linda Garavalia; Brian Garavalia; John A Spertus; Carole Decker
Journal:  J Cardiovasc Nurs       Date:  2009 Sep-Oct       Impact factor: 2.083

4.  Gender-related differences in the presentation, management, and outcomes among patients with acute coronary syndrome from Oman.

Authors:  Kadhim Sulaiman; Prashanth Panduranga; Ibrahim Al-Zakwani
Journal:  J Saudi Heart Assoc       Date:  2010-10-07

5.  Gender differences in clinical presentation and management of patients with acute coronary syndrome in Southwest of Saudi Arabia.

Authors:  Abdullah S Assiri
Journal:  J Saudi Heart Assoc       Date:  2011-01-09

6.  Gender inequality in acute coronary syndrome patients at Omdurman Teaching Hospital, Sudan.

Authors:  Hyder O Mirghani; Mohammed A Elnour; Akasha M Taha; Abdulateef S Elbadawi
Journal:  J Family Community Med       Date:  2016 May-Aug
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.